KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biolife Solutions (BLFS) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Biolife Solutions (BLFS) over the last 16 years, with Q3 2025 value amounting to $5.9 million.

  • Biolife Solutions' Share-based Compensation rose 1079.0% to $5.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $26.6 million, marking a year-over-year decrease of 1171.57%. This contributed to the annual value of $30.9 million for FY2024, which is 698.45% down from last year.
  • Per Biolife Solutions' latest filing, its Share-based Compensation stood at $5.9 million for Q3 2025, which was up 1079.0% from $5.9 million recorded in Q2 2025.
  • Over the past 5 years, Biolife Solutions' Share-based Compensation peaked at $10.7 million during Q4 2024, and registered a low of $1.5 million during Q1 2021.
  • For the 5-year period, Biolife Solutions' Share-based Compensation averaged around $6.3 million, with its median value being $6.0 million (2022).
  • In the last 5 years, Biolife Solutions' Share-based Compensation skyrocketed by 25873.75% in 2022 and then tumbled by 4154.88% in 2024.
  • Over the past 5 years, Biolife Solutions' Share-based Compensation (Quarter) stood at $5.1 million in 2021, then surged by 51.32% to $7.7 million in 2022, then rose by 29.3% to $9.9 million in 2023, then rose by 7.91% to $10.7 million in 2024, then tumbled by 44.78% to $5.9 million in 2025.
  • Its Share-based Compensation stands at $5.9 million for Q3 2025, versus $5.9 million for Q2 2025 and $4.2 million for Q1 2025.